

Company Announcement

Wednesday 18th November 2009

Melbourne, Australia

Manager Companies
Company Announcements Office
Australian Securities Exchange Limited
Level 4, Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam,

Results of Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Yours faithfully,

A handwritten signature in black ink, appearing to be "DK", is located below the "Yours faithfully," text.

Darren Keamy
Company Secretary

1) Adoption of the Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
16,932,926	3,623,111	724,014	1,068,618

The motion was carried as an ordinary resolution on a show of hands

2) Appointment of Grant Thornton Audit Pty Ltd

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
20,116,502	313,486	850,063	1,068,618

The motion was carried as an ordinary resolution on a show of hands

3) Re-election of Mr Stanley McLiesh

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
19,377,353	1,065,480	837,218	1,068,618

The motion was carried as an ordinary resolution on a show of hands

4) Re-election of Dr Helmer Agersborg

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
16,926,404	3,304,574	877,968	1,239,723

The motion was carried as an ordinary resolution on a show of hands

5) Approve Conditional Performance Rights Plan

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
15,759,294	4,845,202	303,580	523,342

The motion was carried as an ordinary resolution on a show of hands

For more information contact:

Darren Keamy

Company Secretary

Clinuvel Pharmaceuticals Limited

T: +61 3 9660 4900

E: investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, afamelanotide for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for afamelanotide can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for afamelanotide is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

**Level 11 / 330 Collins Street
Melbourne, Victoria 3000
Australia**

**T +61 3 9660 4900
F +61 3 9660 4999**

www.clinuvel.com